426 results about "Blood specimen" patented technology

The invention discloses a sugar chain marker combination for predicting prognosis of liver cancer transarterial chemoembolization and application of the sugar chain marker combination. The invention discovers and verifies that the combination composed of NA3Fb, NA4Fb and NA4F2b can be used as a novel marker for evaluating TACE treatment reaction and prognosis by analyzing a serum sugar chain map of a liver cancer patient for the first time. Based on the marker combination, a TACE-GT prognosis scoring model and system are established, and the progression risk of a patient within 12 months after a TACE operation can be effectively distinguished by noninvasively detecting the expression levels of three carbohydrate chains in serum of the patient and calculating a specific score. The detection method provided by the invention is based on a blood sample, and has the advantages of noninvasiveness and convenience, and a risk assessment system can provide individualized curative effect prediction and decision support for clinicians before and after TACE treatment, and has important values for realizing precise treatment of liver cancer and improving prognosis of patients.

In some embodiments, a method for classifying elements of a blood sample is provided, the method including: digitally staining an image of the blood sample using a trained machine learning model to generate a digitally stained image; extracting one or more intermediate features generated by the trained machine learning model during the digital staining of the image; providing the one or more extracted intermediate features to a trained multi-class classifier; and employing the trained multi-class classifier to classify at least one element in the blood sample based on the one or more extracted intermediate features. Many other embodiments are also provided.

A blood cell analyzer (100) and a blood cell analysis method (300). The blood cell analysis method (300) comprises: sucking a blood sample to be tested; preparing a first determination sample and obtaining first optical information; preparing a second determination sample and obtaining second optical information; generating a first leukocyte classification scatter diagram and a second leukocyte classification scatter diagram; determining a first counting result of neutrophils of the to-be-detected blood sample based on the first leukocyte classification scatter diagram and the second leukocyte classification scatter diagram; determining an actual distribution area of neutrophils from the first leukocyte classification scatter diagram; based on a reference distribution region of neutrophils of a reference leukocyte classification scatter diagram of the normal blood sample, determining a leaf-division nucleophore distribution region from the actual distribution region; determining a second counting result of the cells falling into the leaf-separating nucleogranulocyte distribution area; and based on the first counting result and the second counting result, determining a counting result of the rod-shaped nuclear granulocytes in the to-be-detected blood sample.

The invention discloses a prediction marker and a prediction method for acute upper respiratory infection susceptibility. The prediction marker and the prediction method are used for solving the problem that current acute upper respiratory infection susceptibility risk prediction is low in accuracy. The method comprises the following steps: firstly, providing a prediction marker for acute upper respiratory infection susceptibility, wherein the prediction marker is a prediction feature combination obtained by comprehensively considering human health state blood routine data and baseline blood transcriptome data and carrying out feature processing; secondly, providing a prediction method, and obtaining a to-be-detected blood sample; and performing blood analysis based on a to-be-detected blood sample, inputting the obtained blood routine sample and the gene expression sample into a susceptibility prediction model pre-trained based on a prediction marker for susceptibility risk judgment, and obtaining a susceptibility risk assessment result of acute upper respiratory infection of a human body corresponding to the to-be-detected blood sample in a future period of time, therefore, the acute upper respiratory infection susceptibility risk of the human body in a period of time in the future can be simply, quickly and accurately predicted.

This invention discloses a blood purification device and medical system. The blood purification device includes: a device housing; a blood purifier; a blood tubing assembly, the blood tubing assembly including a first blood tubing connecting a human blood vessel to the inlet of the blood purifier and a second blood tubing connecting the outlet of the blood purifier to the human blood vessel; a power assembly including a blood pump for driving blood flow within the blood tubing assembly, a first replenishment pump for allowing anticoagulant solution to flow into the first blood tubing, and / or a second replenishment pump for allowing calcium solution to flow into the second blood tubing; and a blood component analysis component disposed within the device housing, the blood component analysis component being used to detect collected blood samples. This design facilitates the appropriate adjustment of anticoagulant drugs and calcium ions in the blood purification circuit.

The invention discloses an active tuberculosis diagnostic marker, a kit and application thereof. In particular to application of a reagent for detecting a diagnostic marker in preparation of a kit for diagnosing active tuberculosis, the diagnostic marker is a biomarker TRIM22 in a blood sample, and the sequence of the TRIM22 is as shown in SEQ ID NO: 1. According to the invention, TRIM22 in a blood sample is used as a biomarker for detecting active tuberculosis for the first time. Results of ROC curve analysis show that the expression level of TRIM22 in whole blood has good sensitivity and specificity for active tuberculosis diagnosis. Therefore, the invention overcomes the defects of low detection rate, long time consumption and the like of the existing active tuberculosis diagnosis, has the characteristics of good specificity and high sensitivity, and has good clinical application value for the auxiliary diagnosis of the active tuberculosis.

The invention relates to the technical field of infectious disease detection, and discloses a new respiratory infectious disease early warning method, which comprises the following steps: S1, specimen collection and data collection: collecting biological samples of new respiratory infectious disease virus infected individuals and other respiratory infectious disease virus infected individuals, the biological sample comprises a blood sample and a swab sample; meanwhile, basic information of the individuals is collected, wherein the basic information comprises gender, age and respiratory symptom duration; s2, quantitative detection: the biological sample is subjected to quantitative detection by adopting reagents of various respiratory infectious disease viruses, the detection content comprises antigens and antibodies, and the antibodies comprise an I gM antibody, an I gG antibody and an I gA antibody; according to the invention, basic information of individuals and antigen-antibody detection reagent resources of various respiratory infectious disease viruses are deeply integrated, so that the recognition capability of new respiratory infectious disease virus infected individuals is effectively improved.

The invention provides a method and a system for predicting early gastric cancer prognosis by a circulating marker, and relates to the technical field of auxiliary diagnosis. The method comprises the following steps: performing multi-omics detection on a blood sample based on a preset sampling time sequence to obtain a multi-dimensional time sequence characteristic data set containing three groups of heterogeneous data of circulating tumor DNA, exosomes and protein markers; calculating a change slope and a fluctuation variance of the heterogeneous data in adjacent time sequence intervals, constructing a dynamic variation feature matrix in combination with a standard attenuation weighting factor, and deeply mining spatial cross-correlation and sequence dependence features of the matrix to generate a multi-modal fusion feature fingerprint; and performing regression operation on the feature fingerprints by using an integrated learning stack model to obtain a dynamic prognosis risk score, and further retrieving a risk hierarchical mapping table to generate a prognosis evaluation result containing a survival curve. According to the method, multi-modal heterogeneous data can be effectively fused, the biological dynamic characteristics in the tumor postoperative recovery phase are captured, and the accuracy and timeliness of early gastric cancer prognosis prediction are remarkably improved.

The invention relates to the field of medical imaging and clinical data machine learning, and discloses an ICAS stroke risk prediction method and system, and the method comprises the steps: carrying out the preprocessing of image data; clinical data such as past medical history, clinical symptoms and family history of the patient are collected; analyzing related biomarkers of the blood sample to obtain biomarker data, and selecting variables closely related to the stroke risk; then carrying out feature splicing to form a multi-modal fusion feature vector; and finally, training, verifying and testing by adopting a machine learning algorithm, and constructing to obtain an ICAS stroke risk prediction model. And based on the ICAS stroke risk prediction model, generating a stroke risk score for each patient, and generating a clinical decision support strategy. The performance of the stroke risk prediction method and system can be improved continuously, accurate risk prediction can be provided in different clinical environments, and accurate stroke risk assessment and targeted treatment schemes can be provided for ICAS patients.

A microneedle device comprises a device structure, insertable to a living body and being formed with an opened niche at least partially surrounded by walls of micrometric heights above a base of the niche for allowing the niche to be filled with a blood sample upon the insertion. The device also comprises a biosensor configured to sense a bioanalyte in the blood sample and having a sensing element formed on the base. The thickness of the sensing element is less than the micrometric heights of the walls.

The invention discloses a thrombelastogram calibration method, device, system and equipment and a storage medium, and the method comprises the steps: generating an initial thrombelastogram in a process that a blood sample rotates along with a container, through a mechanical torsion signal which drives a suspension wire to move in and after a process that the blood sample forms a blood clot, and collecting the initial thrombelastogram through a mechanical sensor; the method comprises the following steps: generating a light intensity time change chart through near-infrared light signals collected by a spectrograph, and extracting an attenuation rising rate representing a blood sample coagulation rate, an attenuation value representing blood sample coagulation intensity and an attenuation recovery rate representing fibrinolysis after blood sample coagulation, so as to calibrate an initial thromboelastogram and obtain a calibrated thromboelastogram. Therefore, on the basis of the thrombelastogram measured on the basis of the mechanics principle, the attenuation signal measured by the near-infrared optical principle is utilized to calibrate the thrombelastogram, the influence of non-coagulation factor interference on only mechanical signals is reduced, and the accuracy and the reliability of generating the thrombelastogram are improved.

The application discloses application of a product for detecting metabolite levels in serum in preparation of a preparation for diagnosing systemic lupus erythematosus (SLE) and SLE patients with different organ involvement phenotypes and a reagent. The application first uses specific serum biomarkers to assist in screening SLE, SLE with different disease activity and SLE patients with different organ phenotypes, including only kidney involvement systemic lupus erythematosus (KI), only skin involvement systemic lupus erythematosus (SI), only blood system involvement systemic lupus erythematosus (BI) and multi-system involvement systemic lupus erythematosus (MI), thereby opening up a new way for the diagnosis of the field and helping to more accurately diagnose and evaluate the disease progression of SLE. The blood specimen required is small, easy to carry out and has a good application prospect.

The application discloses a blood sample image intelligent recognition and classification system based on computer vision, relates to the technical field of pathological image analysis and computer vision, and comprises the following steps: acquiring an original collected image and performing nonlinear concentration mapping to generate a biochemical layered image containing measured concentration data; locking a cell center and dividing an initial jurisdiction through center response calculation to construct an ideal simulation single-cell layer; calculating a difference image of a simulation superimposed image and a measured image, iteratively correcting the simulation layer in a reverse direction by using concentration difference data until an independent single-cell layer containing recovered texture is obtained; and finally generating an overlapping complexity weight map based on the difference image, constructing a multi-dimensional feature data packet and inputting the multi-dimensional feature data packet into a convolutional neural network to output a classification result; the application effectively solves the recognition problem caused by cell overlapping in high-density samples by combining physical model decoupling with deep learning.

The invention provides a computer-implemented method and system for non-invasive and step-by-step prediction of cancer risks and a storage medium. The method comprises the following steps: (1) determining a cancer signal score based on the level of a biomarker in a blood sample of a subject; (2) comparing the cancer signal score with a preset threshold value, and determining a primary screening positive subject; (3) further performing cancer risk determination and cancer species prediction by adopting an NGS method on the basis of the primarily screened positive subjects; wherein the biomarker is selected from at least one of AFP (Alpha Fetal Protein), CA125, CA15-3, CA19-9, CA72-4, CEA (Carcino Embryonic Acid), CYFRA (Cytochrome Factor Receptor Amplification) 21-1, ProGRP (Proso-Growth Radical Polymerase Chain Reaction), SCCA (Sequence

The invention discloses a swelling microneedle patch and a preparation method thereof. The swelling microneedle patch comprises a backing and a swelling microneedle array adhered to the backing, the swelling microneedle array comprises a plurality of microneedles; the microneedle is in the shape of a cone or a rectangular pyramid; the height of the microneedle is 100 to 1000 [mu] m; the diameter of the tip end of the microneedle is 5-30 microns; the diameter of the bottom of the microneedle is 50-500 [mu] m; and the center-to-center distance between every two adjacent microneedles is 50-2000 microns. The swelling microneedle patch provided by the invention can overcome the barrier action of cuticle to penetrate subcutaneously and absorb subcutaneous tissue interstitial fluid, and is simple in preparation process, low in cost and high in universality. The patch is combined with a colloidal gold lateral chromatography test strip, so that the limitations that in-vitro diagnosis of infectious diseases depends on a blood sample, professional medical personnel are needed for operation, the subject compliance is poor and the like can be solved, and the patch is suitable for rapid screening and diagnosis of the infectious diseases.

The invention discloses an anti-coagulation blood specimen collection oscillation device, and relates to the technical field of blood collection, and the anti-coagulation blood specimen collection oscillation device comprises a base and a main body forming the device; the movable mechanism is assembled at the upper end of the base and is used for uniformly and automatically oscillating the sample in a reciprocating manner; the locking mechanism is assembled at the upper end of the movable mechanism and is used for generating a trigger signal when the sample main body is inserted in place; according to the anti-coagulation blood sample collection oscillation device, stable positioning of a sample in the treatment process can be ensured through the locking mechanism, displacement caused by vibration or external interference is avoided, the accuracy of an experimental result is ensured, meanwhile, downward pressure is applied to help to correct the position of the sample, deviation caused by the shape of the sample or a non-uniform container is further prevented, and the sampling accuracy is improved. And the sample processing stability is improved.

To accurately and efficiently detect the coagulation state of a blood sample in a blood collection tube in a short time by a simple method.SOLUTION: A blood property testing device 1 for testing a property of a blood sample stored in a blood collection tube includes: sample conveying means 10 capable of conveying the blood collection tube in which the blood sample is stored; an ultrasonic probe 6 arranged in a conveying path by the sample conveying means 10 and capable of transmitting ultrasonic waves to the blood sample in the blood collection tube to be conveyed and receiving reflected waves; an ultrasonic image generating part 72 for generating an ultrasonic tomographic image of the blood sample based on the reflected waves; and a blood property detecting part 74 for detecting the blood property of the blood sample based on the generated ultrasonic tomographic image.SELECTED DRAWING: Figure 2

This invention provides a methylation biomarker for detecting gastric cancer and its application, relating to the field of molecular biomedical technology. This invention provides a combination of methylation biomarkers for early, non-invasive identification of gastric cancer and their application. Based on the measured expression levels of methylation biomarkers in blood samples from patients with and without gastric cancer, biomarkers for identifying gastric cancer are provided. The biomarker combination of this invention can not only assist clinicians in predicting and diagnosing the risk of patients developing gastric cancer, but also serve as a tool for screening high-risk populations for gastric cancer, helping patients to detect and treat the disease early. Moreover, compared to current gastric cancer early screening products and existing technologies, the detection process of this invention is non-invasive, has higher sensitivity and specificity, the detection method is mature and rapid, the cost is low, the safety is high, and it is convenient for large-scale clinical application.

The invention relates to the technical field of molecular detection, in particular to a method, a system, a kit and a probe for detecting BRCA2 gene mutation. The detection method comprises the following steps: carrying out pretreatment and PCR amplification on a blood sample, carrying out a hybridization reaction with a probe to obtain a sample, detecting the sample based on an SERS technology, and collecting an SERS spectrum. Whether BRCA2 gene mutation exists or not is judged by identifying characteristic double peaks of a cy3 fluorophore at 1188 cm <-1 > and 1393 cm <-1 >, and the whole detection process can be completed within 2 hours. According to the scheme, the region, carrying the BRCA2 gene, on the DNA can be amplified through the specific primer pair, then the DNA is specifically combined through the improved oligonucleotide probe, and detection is achieved through the reporter molecule on the oligonucleotide probe; therefore, the detection method provided by the scheme has the advantages of high detection speed, high sensitivity and high detection result accuracy, and the problems of long time consumption and high cost of the traditional PCR or NGS technology are effectively solved.

The application relates to a blood biomarker for evaluating and diagnosing Parkinson's disease and an application thereof. The blood biomarker is SERPINA3 and / or alpha-Syn. By using the biomarker as a diagnostic biomarker for Parkinson's disease, early diagnosis of Parkinson's disease can be assisted by detecting the SERPINA3 level and the alpha-Syn level in a blood sample, the trauma is small, the operation is simple, and the method is suitable for most patients and has high patient acceptance; and the SERPINA3 and alpha-Syn levels in the blood sample can be determined by a photochemical luminescence detection method, the detection sensitivity is high, the accuracy is high, and early, efficient and high-precision diagnosis of Parkinson's disease can be realized.

Provided in the present application are a computer implemented method for non-invasive stepwise prediction of cancer risks, and a system and a storage medium. The aforementioned method comprises: (1) determining a cancer signal score on the basis of the level of a biomarker in a blood sample from a subject; (2) comparing the cancer signal score with a predetermined threshold value to determine a positive subject via preliminary screening; and (3) on the basis of the positive subject from the preliminary screening, further performing cancer risk determination and cancer type prediction by using an NGS method, wherein the biomarker includes at least one selected from AFP, CA125, CA15-3, CA19-9, CA72-4, CEA, CYFRA 21-1, ProGRP, SCCA and PSA.

This invention relates to the field of fatty acid detection technology, specifically to a method for determining 11 polyunsaturated fatty acids based on LC-MS / MS. The method includes: preparing a calibration solution; hydrolyzing bound fatty acids in a blood sample, adding a precipitant, centrifuging, and collecting the supernatant as the test sample; detecting the test sample using liquid chromatography-tandem mass spectrometry, and substituting the detection results into the calibration curve equation to obtain the content of the 11 polyunsaturated fatty acids in the test sample. This method can rapidly and accurately detect the content of 11 polyunsaturated fatty acids, providing a more accurate basis for clinical diagnosis and assisting in the early detection and treatment of diseases; at the same time, it can also provide more targeted nutritional advice to individuals, promoting health management.

The present disclosure relates generally to compositions, systems, and methods for lysing blood samples comprising an infectious agent, for example a bacteria, or a fungus, while maintaining viability of the infectious agent for subsequent characterization, for example phenotyping or genotyping. A lysing composition may include one or more surfactants, such as one or more detergents. A lysing composition may include lysing agent including one or more salts. A lysing composition may include one or more enzymes to break down one or more lyses byproducts, such as nucleic acids and / or protein aggregates.

The present application relates to the technical field of biomedical equipment, and particularly provides a blood type detector and a shaking and mixing device of the blood type detector, aiming to solve the problem that the mixing effect of blood samples and detection reagents of the existing blood type detector is poor, thereby affecting the detection result. To this end, the shaking and mixing device comprises a shaking and mixing mechanism and a cup loading component mounted on the shaking and mixing mechanism, the cup loading component is used for loading a reaction cup, and the shaking and mixing mechanism can vibrate with the cup loading component and the reaction cup in the cup loading component to mix the blood sample and the detection reagent in the reaction cup. By arranging the cup loading component on the shaking and mixing mechanism, the reaction cup can be directly fixed on the shaking and mixing mechanism, so that the vibration generated by the shaking and mixing mechanism can be better transmitted to the reaction cup, thereby improving the mixing effect of the blood sample and the detection reagent in the reaction cup, and further improving the accuracy of the detector.

The embodiment of the application discloses a blood analyzer and a control method, wherein the blood analyzer comprises a sample feeding mechanism, a sample taking mechanism, a mixing mechanism, a transfer mechanism, a sample sucking mechanism, a reaction mechanism and a controller. The sample feeding mechanism, the sample taking mechanism, the mixing mechanism, the transfer mechanism and the sample sucking mechanism of the blood analyzer are sequentially matched by the controller. When the blood analyzer works, at least two different blood samples perform the mixing operation. When one of the mixed blood samples performs other subsequent operations, the other sample can continue to mix in time, so that the time difference existing in different stages of the detection process is fully utilized, the time of batch sample detection is saved, and the detection efficiency of the blood sample is improved.

The present invention relates to an innovative blood collection system including a blood collection device, or blotter, designed to efficiently and in an environmentally responsible manner collect blood samples from finger prick or other wounds, and then optionally provide a convenient vehicle for the blood sample to be sent for processing and analysis without having to transport the patient to a clinic and back.

The invention provides a methylation marker combination for identifying and diagnosing benign and malignant thyroid nodules or diagnosing thyroid cancer. The methylation marker combination comprises methylation TSHR, NIS and TPO genes or fragments thereof. In addition, the invention further provides a thyroid cancer diagnosis product and device based on the methylation marker combination and application of the thyroid cancer diagnosis product and device in thyroid nodule benign and malignant identification and thyroid cancer diagnosis. Whether a thyroid tissue sample or a blood sample is taken as a detection object, the methylation marker combination can realize efficient and sensitive diagnosis of thyroid cancer, and especially has outstanding performance in early thyroid cancer diagnosis, so that the methylation marker combination has a good application prospect. And the kit has important clinical application value and practical significance for early screening and diagnosis of thyroid cancer.